Journal of Urban Health

, Volume 76, Issue 4, pp 448–460 | Cite as

Needle-exchange attendance and health care utilization promote entry into detoxification

  • Steffanie A. Strathdee
  • David D. Celentano
  • Nina Shah
  • Cynthia Lyles
  • Veronica A. Stambolis
  • Grace Macalino
  • Kenrad Nelson
  • David Vlahov

Abstract

This study was undertaken to identify factors associated with entry into detoxification among injection drug users (IDUs), and to assess the role of needle-exchange programs (NEPs) as a bridge to treatment. IDUs undergoing semiannual human immunodeficiency virus (HIV) tests and interviews were studied prospectively between 1994 and 1998, during which time an NEP was introduced in Baltimore. Logistic regression was used to identify independent predictors of entry into detoxification, stratifying by HIV serostatus. Of 1,490 IDUs, similar proportions of HIV-infected and uninfected IDUs entered detoxification (25% vs. 23%, respectively). After accounting for recent drug use, hospital admission was associated with four-fold increased odds of entering detoxification for HIV-seronegative subjects. Among HIV-infected subjects, hospital admission, outpatient medical care, and having health insurance independently increased the odds of entering detoxification. After accounting for these and other variables, needle-exchange attendance also was associated independently with entering detoxification for both HIV-infected (adjusted odds ratio [AOR]=3.2) and uninfected IDUs (AOR=1.4). However, among HIV-infected subjects, the increased odds of detoxification associated with needle exchange diminished significantly over time, concomitant with statewide reductions in detoxification admissions. These findings indicate that health care providers and NEPs represent an important bridge to drug abuse treatment for HIV-infected and uninfected IDUs. Creating and sustaining these linkages may facilitate entry into drug abuse treatment and serve the important public health goal of increasing the number of drug users in treatment.

Key Words

Detoxification HIV/AIDS Injection Drug Use Needle-exchange Programs Substance Abuse Treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lurie P, Reingold A, Bower B, et al.The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Vol 1. Atlanta, GA: Centers for Disease Control and Prevention; 1993.Google Scholar
  2. 2.
    Strathdee SA, van Ameijden E, Mesquita F, et al. Can HIV epidemics among injection drug users be prevented?AIDS. 1998;12(suppl A):S71-S79.PubMedGoogle Scholar
  3. 3.
    Normand J, Vlahov D, Moses LE.Preventing HIV Transmission: the Role of Sterile Needles and Bleach. Washington, DC: National Academy Press; 1995.Google Scholar
  4. 4.
    Hurley S, Jolley D, Kaldor J. Effectiveness of needle-exchange programmes for prevention of HIV infection.Lancet. 1997;349:1797–1800.CrossRefPubMedGoogle Scholar
  5. 5.
    Paone D, Clark J, Shi Qiuhu, et al. Syringe exchange in the United States, 1996: a national profile.Am J Public Health. 1999:89(1):43–46.PubMedGoogle Scholar
  6. 6.
    Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment?J Subst Abuse Treat. 1998;15(3):183–191.CrossRefPubMedGoogle Scholar
  7. 7.
    Vlahov D, Junge B, Brookmeyer R, et al. Reductions in high-risk drug use behaviours among participants in the Baltimore needle exchange program.J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:400–406.PubMedGoogle Scholar
  8. 8.
    Heimer R, Kaplan EH, O'Keefe E, et al. Three years of needle exchange in New Haven: what have we learned?AIDS Public Policy J. 1994;9:59–74.Google Scholar
  9. 9.
    Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D.Drug abuse treatment success among needle exchange participants.Public Health Rep. 1998;113(suppl 1):129–139.PubMedGoogle Scholar
  10. 10.
    Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention.Public Health Rep. 1998;113(1):97–105.PubMedGoogle Scholar
  11. 11.
    Centers for Disease Control and Prevention (US). Risk behaviors for HIV transmission among intravenous drug users not in treatment—United States.MMWR Morb Mortal Wkly Rep. 1990;39:273–276.Google Scholar
  12. 12.
    Schuster CR. Intravenous drug use and HIV prevention.Public Health Rep. 1988;103:261–263.PubMedGoogle Scholar
  13. 13.
    Vlahov D, Anthony JC, Munoz A, et al. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods.J Drug Issues. 1991; 21(4):759–776.Google Scholar
  14. 14.
    Anthony JC, Vlahov D, Nelson KE. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1.Am J Epidemiol. 1991;134:1175–1189.PubMedGoogle Scholar
  15. 15.
    Zeger S, Liang KY. Longitudinal data analysis for discrete and continuous outcomes.Biometrics. 1986;42:121–130.PubMedGoogle Scholar
  16. 16.
    Department of Health and Human Service, Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies.National Admissions to Substance Abuse Treatment Services, the Treatment Episode Data Set (TEDS) 1992–1996. Rockville, MD: Office of Applied Science; 1997.Google Scholar
  17. 17.
    Alcohol and Drug Abuse Administration.Trends and Patterns in Maryland Alcohol and Drug Abuse Treatment 1997. Baltimore, MD: Maryland Department of Health and Mental Hygiene; 1998.Google Scholar
  18. 18.
    Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and re-use: effects of syringe exchange programs in four cities.J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S37-S44.PubMedGoogle Scholar
  19. 19.
    Schechter MT, Strathdee SA, Cornelisse PGA, et al. Do needle exchange programs increase the spread of HIV among injection drug users: an investigation of the Vancouver outbreak.AIDS. 1999;13:F45-F51.CrossRefPubMedGoogle Scholar
  20. 20.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Science, Drug Abuse Network (DAWN) Series.D-3, Year-End Preliminary Estimates from the 1996 Drug Abuse Warning Network. Rockville, MD: Office of Applied Science; 1997.Google Scholar
  21. 21.
    CESAR.Herion Related Emergency Report Visits in Baltimore Metro Area Highest Among Cities in DAWN System. Baltimore, MD: Drug Awareness Warning Network; 1995. Advance Report Number 11.Google Scholar
  22. 22.
    Lewin VHI, Inc.An Analysis of Pilot Data on the Cost of Substance Abuse Treatment: Unit Costs From 77 Service Delivery Units. Technical Report to the Center for Substance Abuse Treatment. Fairfax, VA: National Evaluation Data and Technical Assistance Center (NEDTAC); 1996.Google Scholar
  23. 23.
    Shutz CG, Rapiti E, Vlahov D, et al. Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injecting drug users.Drug Alcohol Depend. 1994;36:129–138.Google Scholar
  24. 24.
    Latkin C, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users.Addiction. 1993;88:517–526.CrossRefPubMedGoogle Scholar
  25. 25.
    De Irala J, Bigelow C, McCusker J, et al. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population.Am J Epidemiol. 1996;143:725–731.PubMedGoogle Scholar
  26. 26.
    Graeven DB, Graeven KA. Treated and untreated addicts: factors associated with participation in treatment and cessation of heroin use.J Drug Issues. 1983;83(2):207–218.Google Scholar
  27. 27.
    McCusker J, Bigelow C, Luippold R, et al. Outcomes of a 21-day drug detoxification program: retention, transfer to further treatment, and HIV risk reduction.Am J Drug Alcohol Abuse. 1995;21(1):1–16.PubMedGoogle Scholar

Copyright information

© The New York Academy of Medicine 1999

Authors and Affiliations

  • Steffanie A. Strathdee
    • 1
  • David D. Celentano
    • 1
  • Nina Shah
    • 1
  • Cynthia Lyles
    • 1
  • Veronica A. Stambolis
    • 1
  • Grace Macalino
    • 1
  • Kenrad Nelson
    • 1
  • David Vlahov
    • 1
    • 2
  1. 1.Department of EpidemiologyJohns Hopkins School of Public HealthBaltimore
  2. 2.New York Academy of MedicineNew York City

Personalised recommendations